Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Other Disease Areas
Filter     Order     Display # 
Date Item Title
30 Sep 2006 VIVUS Announces Results of ALISTA Phase 2b Study
30 Sep 2006 First phase II acne study finalised
27 Sep 2006 BioXell Reports Preliminary Phase IIa Results in Non-Bacterial Chronic Prostatitis
27 Sep 2006 MacuSight(TM) Initiates First Phase I Study of Novel Ophthalmic Drug Candidate
22 Sep 2006 Alcon's TRAVATAN(R) Z Solution Approved by FDA for Treatment of Glaucoma and Ocular Hypertensive Patients
21 Sep 2006 Axcan Announces Results of the ITAX North American Phase III Clinical Study in Functional Dyspepsia
20 Sep 2006 Initiation of Phase II Clinical Study of Novel Ophthalmic Product
20 Sep 2006 Nymox Announces Positive Results from Completed Phase 2 BPH Drug Trial
15 Sep 2006 After 40 years waiting, glimmer of light at end of tunnel for SLE sufferers
14 Sep 2006 Dynogen Initiates Phase 1b Trial of DDP733 in Gastroesophageal Reflux Disease (GERD)
13 Sep 2006 SurModics I-vation(TM) Intravitreal Implant Six Month Clinical Study Data Presented at the American Society of Retina Specialists Meeting; Well Tolerated, 100% of Patients Maintained or Improved Vision
13 Sep 2006 Neurocrine Biosciences Announces Results From Follow-Up Phase II Study With Its Orally Active GnRH Receptor Antagonist in Endometriosis
13 Sep 2006 OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213)
12 Sep 2006 Acuity Pharmaceuticals Reports Positive Phase II Results for Bevasiranib in Wet AMD
07 Sep 2006 Can-Fite BioPharma Received Israeli MoH Approval to Conduct a Clinical Trial Evaluating the Efficacy of CF101 in Patients with Dry Eye Syndrome
06 Sep 2006 Spiriva(R) significantly improves lung function in patients with mild COPD
06 Sep 2006 GlaxoSmithKline and Adolor Report Top-Line Results From Phase 3 Studies of Alvimopan
06 Sep 2006 Otologics Announces a Clinical Research Study for a New Fully Implantable Hearing Device
06 Sep 2006 MediciNova Announces Completion of Enrollment in a Phase II/III Interstitial Cystitis Trial with MN-001
06 Sep 2006 Extensive Post-License Data Reaffirm Clinical Safety Profile of Prolastin(R)
06 Sep 2006 Pine Tree Bark Reduces Diabetic Leg Ulcers
29 Aug 2006 First European approval in Switzerland for Lucentis(R) as a breakthrough treatment for a leading cause of blindness in people over age 50
23 Aug 2006 Wyeth and Progenics Pharmaceuticals Announce Initiation of Phase 2 Clinical Trial of Oral Methylnaltrexone
22 Aug 2006 Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
18 Aug 2006 Advanced Refractive Achieves Early Milestone
16 Aug 2006 Results of Phase 2 Study of Tolevamer for C. difficile-Associated Diarrhea Published in Clinical Infectious Diseases
16 Aug 2006 Iomai Launches Phase 2 Clinical Study of Vaccine Patch for Travelers' Diarrhea
12 Aug 2006 Amarillo Biosciences IND Application Passes FDA Review
10 Aug 2006 Sirna Therapeutics Reports Final Results From Phase 1 Study On Its RNAi-Based Therapeutic For Age-Related Macular Degeneration
10 Aug 2006 NexMed Develops Room Temperature Formulation of Alprox-TD for Erectile Dysfunction
09 Aug 2006 MacuSight Announces FDA Acceptance of IND for Novel Ophthalmic Drug Candidate
03 Aug 2006 Palatin Technologies and King Pharmaceuticals Report Results of a Clinical Study Evaluating Bremelanotide in Post-Menopausal Female Sexual Dysfunction Patients
03 Aug 2006 Glenmark Receives Nod From DCGI To Initiate Phase II Trials In India For Novel Anti-diarrhoeal Product, Crofelemer
03 Aug 2006 MOVIPREP(R) Granted FDA Marketing Approval
02 Aug 2006 Akorn, Inc. Receives U.S. IND Clearance for the Clinical Development of AK-1015, an NDA Drug Product for Ocular Anesthesia
01 Aug 2006 Alliance Pharmaceutical Corp. Provides Clinical Study Update
29 Jul 2006 Barrier Therapeutics Receives FDA Approval of Xolegel(TM) Gel for the Treatment of Seborrheic Dermatitis
28 Jul 2006 BioXell Announces Phase II Results For Elocalcitol In Overactive Bladder
28 Jul 2006 New Study Demonstrates Significant Differences in Migration Characteristics Between Botulinum Toxin Type A Formulations: (Botox(R) and Dysport(R))
27 Jul 2006 Inspire Initiates Phase 3 Clinical Trial of Denufosol Tetrasodium in Cystic Fibrosis Patients
25 Jul 2006 TyRx Pharma, Inc., Announces FDA Clearance of PIVIT(TM) AB, a Novel Antimicrobial-Coated Surgical Mesh
21 Jul 2006 Fresenius Medical Care Receives Regulatory Approval for New Phosphate Binding Agent in Germany
20 Jul 2006 DNAPrint Pharmaceutical Completes Sterility Testing on Anemia Drug Cell Lines for Clinical Development
20 Jul 2006 Seikagaku to Begin Clinical Trials of Injectable Hyaluronic Acid Gel for Knee Osteoarthritis Treatment in US
19 Jul 2006 Implanon Contraceptive Implant Receives Approval in United States
19 Jul 2006 Cambrex and Ortec Submit to FDA a Humanitarian Device Exemption (HDE) for OrCel(R) to Treat Epidermolysis Bullosa Patients
19 Jul 2006 Enzo Biochem Announces Approval for Phase II Double-Blind Clinical Trial of EGS21 for Non-Alcoholic Steatohepatitis (NASH)
19 Jul 2006 FOSRENOL® demonstrates effective phosphate control with as few as three tablets a day
18 Jul 2006 Phase 2 and Phase 3 Clinical Trials of TH-070 in Benign Prostatic Hyperplasia (BPH) Do Not Meet Primary Endpoint
18 Jul 2006 TOPIGEN Reports Positive Therapeutic Results from Initial Phase II Trial Studying Inhaled TPI-ASM8 in Patients with Mild-to-Moderate Asthma
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 801 - 850 of 1045

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Janus Kinase (JAK) Inhibitors

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics